AmerisourceBergen (NYSE:ABC) and biOasis Technologies (OTCMKTS:BIOAF) are both medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their risk, analyst recommendations, earnings, valuation, institutional ownership, dividends and profitability.
Institutional and Insider Ownership
64.6% of AmerisourceBergen shares are owned by institutional investors. 27.3% of AmerisourceBergen shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.
AmerisourceBergen pays an annual dividend of $1.60 per share and has a dividend yield of 1.9%. biOasis Technologies does not pay a dividend. AmerisourceBergen pays out 24.7% of its earnings in the form of a dividend. AmerisourceBergen has increased its dividend for 13 consecutive years.
This is a breakdown of recent recommendations and price targets for AmerisourceBergen and biOasis Technologies, as reported by MarketBeat.
||Strong Buy Ratings
AmerisourceBergen presently has a consensus target price of $101.23, indicating a potential upside of 17.74%. Given AmerisourceBergen’s higher possible upside, equities analysts clearly believe AmerisourceBergen is more favorable than biOasis Technologies.
Risk and Volatility
AmerisourceBergen has a beta of 0.94, indicating that its stock price is 6% less volatile than the S&P 500. Comparatively, biOasis Technologies has a beta of 0.71, indicating that its stock price is 29% less volatile than the S&P 500.
Earnings & Valuation
This table compares AmerisourceBergen and biOasis Technologies’ revenue, earnings per share and valuation.
||Earnings Per Share
AmerisourceBergen has higher revenue and earnings than biOasis Technologies.
This table compares AmerisourceBergen and biOasis Technologies’ net margins, return on equity and return on assets.
||Return on Equity
||Return on Assets
AmerisourceBergen beats biOasis Technologies on 12 of the 14 factors compared between the two stocks.
AmerisourceBergen Corporation sources and distributes pharmaceutical products in the United States and internationally. Its Pharmaceutical Distribution segment distributes brand-name and generic pharmaceuticals, over-the-counter healthcare products, home healthcare supplies and equipment, outsourced compounded sterile preparations, and related services to various healthcare providers, including acute care hospitals and health systems, independent and chain retail pharmacies, mail order pharmacies, medical clinics, long-term care and other alternate site pharmacies, and other customers. It also provides pharmacy management, staffing, and other consulting services; supply management software to retail and institutional healthcare providers; and packaging solutions to various institutional and retail healthcare providers. In addition, this segment distributes plasma and other blood products, injectable pharmaceuticals, vaccines, and other specialty products; provides other services primarily to physicians who specialize in various disease states, primarily oncology, as well as to other healthcare providers, including hospitals and dialysis clinics; and offers data analytics, outcomes research, and additional services for biotechnology and pharmaceutical manufacturers. The company's Other segment provides integrated manufacturer services, such as clinical trial support, product post-approval, and commercialization support; offers specialty transportation and logistics services for the biopharmaceutical industry; and sells pharmaceuticals, vaccines, parasiticides, diagnostics, micro feed ingredients, and various other products to customers in both the companion animal and production animal markets, as well as provides demand-creating sales force services to manufacturers. AmerisourceBergen Corporation was founded in 1985 and is headquartered in Chesterbrook, Pennsylvania.
About biOasis Technologies
biOasis Technologies, Inc. is a biopharmaceutical company focuses on research and development for the diagnosis and treatment of neurological disease and disorders such as brain cancers, neurodegenerative diseases, and metabolic disorders. Its products include Transcend program as its proprietary carrier, p97, and components thereof, to deliver therapeutics and imaging agents across the blood brain barrier. The company was founded by Robin B. Hutchison on November 3, 2006 and is headquartered in Vancouver, Canada.
Receive News & Ratings for AmerisourceBergen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AmerisourceBergen and related companies with MarketBeat.com's FREE daily email newsletter.